北陆药业(300016) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥211,788,545.82, representing a 2.79% increase compared to the same period last year[3]. - The net profit attributable to shareholders was -¥7,659,831.39, a decrease of 150.37% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was -¥13,380,222.21, a decline of 331.66% compared to the previous year[4]. - The company reported a basic earnings per share of -¥0.0156, a decrease of 150.32% year-on-year[4]. - Net profit for Q3 2023 was a loss of ¥4,214,435.41, compared to a profit of ¥42,150,937.30 in Q3 2022, indicating a substantial decline in profitability[33]. - The company reported a basic earnings per share of ¥0.0040 for Q3 2023, down from ¥0.1125 in the same quarter last year[33]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥2,871,051,249.22, an increase of 1.86% from the end of the previous year[4]. - The total liabilities amount to 327,245,220.69 CNY, an increase from 302,669,059.51 CNY at the beginning of the year[25]. - The company has a long-term debt of 130,998,527.76 CNY, up from 89,780,000.00 CNY[25]. - The total liabilities increased to ¥985,577,661.01 in Q3 2023 from ¥895,388,823.96, reflecting a rise in financial obligations[31]. - The total equity attributable to shareholders decreased to ¥1,744,333,418.93 from ¥1,776,400,975.93, showing a decline in shareholder value[31]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥61,225,996.09, a decrease of 35.47% year-on-year[11]. - Cash flow from operating activities for Q3 2023 was ¥61,225,996.09, down from ¥94,876,544.89 in the previous year, indicating reduced cash generation[37]. - The net cash flow from investing activities was -¥107,546,400, an increase of 76.61% year-on-year, primarily due to a reduction in bank wealth management purchases[12]. - The cash flow from investment activities was ¥447,373,940.30 in Q3 2023, a decrease from ¥577,025,919.23, indicating reduced investment inflows[37]. - The net cash flow from financing activities was 46,618,494.57, a significant improvement from -142,969,483.83 in the previous period[39]. - The cash and cash equivalents at the end of the period amounted to 736,672,781.82, compared to 352,753,797.22 in the previous period[39]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,978[14]. - The largest shareholder, Wang Daixue, holds 19.87% of the shares, totaling 97,748,327 shares[14]. - The total number of restricted shares at the end of the period is 803,025, with 58,875 shares released from restriction during the period[19]. - The company has a total of 4,176,753 shares held by CITIC Securities Co., Ltd., representing 0.85% of the total shares[16]. Research and Development - Research and development expenses for the year-to-date amounted to ¥86,346,500, representing a 33.70% increase compared to the previous year[11]. - Research and development expenses increased to ¥86,346,507.94 in Q3 2023, up from ¥64,582,430.73, highlighting a focus on innovation[31]. Adjustments and Audits - The company has not undergone an audit for the third quarter report[43]. - The adjustments were made in accordance with the new accounting standards effective from January 1, 2023[41]. - Deferred tax assets increased from 36,153,038.87 to 39,319,658.04 after adjustments[42]. - Deferred tax liabilities rose from 55,450,110.33 to 58,564,840.81 following the adjustments[42]. - The net profit attributable to shareholders increased from 11,206,263.74 to 11,230,391.12 after adjustments[42].